Former U.S. President Barack Obama's visit to Oslo has sparked significant interest, as he engages in a series of high-profile meetings and public appearances. During his stay, Obama participated in a discussion event titled 'A Conversation with President Barack Obama' at Oslo Spektrum, where he shared insights on artificial intelligence's impact on middle-class jobs and lauded the Scandinavian countries for their societal structures. 'There are many things the Scandinavian countries have gotten right. You've been smart in building up several societal institutions,' Obama remarked, according to VG.

Obama's itinerary also included a meeting with Nicolai Tangen, the CEO of Norway's Oil Fund, where they discussed the global economy, geopolitics, and the general situation in the U.S. This meeting underscores the ongoing dialogue between global leaders and financial experts on pressing economic challenges. The Oil Fund's communication chief, Line Aaltvedt, confirmed the discussions, highlighting the importance of such exchanges in today's interconnected world.

Further emphasizing the significance of Obama's visit, the former president is scheduled to meet with King Harald, Crown Princess Mette-Marit, and Prime Minister Jonas Gahr Støre. These meetings are expected to cover a range of topics, from bilateral relations to global issues, reflecting Norway's active role on the international stage. Støre expressed his anticipation for the meeting, noting it would be 'both interesting, pleasant, and exciting to meet him again.'

Obama's visit to Oslo not only highlights his continued influence in global affairs but also Norway's position as a key player in discussions on economic and geopolitical matters. With ticket prices for his public appearance ranging from 1255 to 5130 kroner, the event attracted a wide audience, eager to hear the former president's perspectives. As Obama's engagements in Oslo demonstrate, the intersections of politics, economy, and society remain central to addressing the challenges of our time.

Inozyme Pharma, Inc. has reported encouraging interim data from its ENERGY 3 trial, showcasing INZ-701's potential to alter the disease trajectory in patients with ENPP1 Deficiency. The clinical-stage biopharmaceutical company highlighted sustained increases in phosphate levels alongside a favorable safety and immunogenicity profile, marking a significant step forward in addressing this rare disease.

The ENERGY 3 trial, which completed enrollment in January 2025, is on schedule to deliver topline data in the first quarter of 2026. Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme Pharma, expressed optimism about the trial's progress, noting the absence of patient dropouts, dose adjustments, or discontinuations. This consistency across key metrics underscores the potential of INZ-701 to become the first approved therapy for ENPP1 Deficiency, a condition with significant unmet medical needs.

Adding to the company's momentum, Petra Duda, M.D., Ph.D., has been appointed as Chief Medical Officer. Her expertise is expected to bolster Inozyme Pharma's clinical development efforts as it advances INZ-701 through pivotal trials. The appointment comes at a critical juncture, with the company poised to make significant strides in rare disease therapeutics.

As Inozyme Pharma continues to navigate the clinical development landscape, the progress of the ENERGY 3 trial and the strategic addition to its leadership team underscore its commitment to innovation in rare disease treatment. With the anticipation of topline data in early 2026, the medical and investment communities are closely watching INZ-701's journey toward potential approval and its impact on patients with ENPP1 Deficiency.